Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Beijing Kejing Biotechnology Co., Ltd.
Eastern Cooperative Oncology Group
NKGen Biotech, Inc.
National Cancer Institute (NCI)